Nektar Therapeutics (NKTR)
NASDAQ: NKTR · Real-Time Price · USD
0.932
-0.025 (-2.58%)
At close: Feb 21, 2025, 4:00 PM
0.940
+0.008 (0.85%)
After-hours: Feb 21, 2025, 7:21 PM EST
Nektar Therapeutics Employees
Nektar Therapeutics had 137 employees as of December 31, 2023. The number of employees decreased by 79 or -36.57% compared to the previous year.
Employees
137
Change (1Y)
-79
Growth (1Y)
-36.57%
Revenue / Employee
$679,832
Profits / Employee
-$1,228,474
Market Cap
171.95M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 72,000 |
NKTR News
- 12 days ago - Nektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Moderate-to-Severe Atopic Dermatitis - PRNewsWire
- 6 weeks ago - Nektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AD Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Moderate-to-Severe Atopic Dermatitis - PRNewsWire
- 2 months ago - Nektar Therapeutics Announces NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Patients with Relapsed or Refractory Large B-cell Lymphoma at the 66th Annual ASH Meeting - PRNewsWire
- 3 months ago - Nektar Therapeutics Presents First Preclinical Data from Novel CSF-1 Program, NKTR-422, at 2024 American College of Rheumatology (ACR) Convergence - PRNewsWire
- 3 months ago - Multiple Catalysts Ahead For Nektar Therapeutics - Seeking Alpha
- 3 months ago - Nektar Therapeutics (NKTR) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Nektar Therapeutics Reports Third Quarter 2024 Financial Results - PRNewsWire
- 3 months ago - Nektar and Collaborators Present Late-breaking Results from Phase 2 Study of NKTR-255 for the Treatment of Radiation Induced Lymphopenia in Locally Advanced Non-Small Cell Lung Cancer Patients at Society for Immunotherapy of Cancer (SITC) Annual Meeting - PRNewsWire